[New ESC guidelines 2019 for the treatment of supraventricular tachycardia]

Area of Science:

• Cardiology
• Electrophysiology

Background:

• Supraventricular tachycardia (SVT) management guidelines have been updated by the European Society of Cardiology (ESC) in 2019.
• Catheter ablation has emerged as a safe and effective treatment for SVT, driven by recent technical advancements.

Purpose of the Study:

• To outline the updated European guidelines for managing supraventricular tachycardia (SVT).
• To emphasize the shift towards catheter ablation as a primary treatment modality for SVT.
• To refine recommendations for antiarrhythmic drug therapy and address SVT management during pregnancy.

Main Methods:

• Review and synthesis of current evidence on SVT management.
• Development of updated clinical recommendations by the ESC.
• Inclusion of specific guidance for pregnant patients with SVT.

Main Results:

• Catheter ablation is recommended as a first-line treatment for most SVT patients, following a discussion of risks and benefits.
• Most previously used antiarrhythmic drugs have been downgraded due to proarrhythmic potential, with beta-blockers and calcium channel blockers remaining options.
• New guidelines address SVT in pregnancy, recommending avoidance of antiarrhythmic drugs in the first trimester and offering catheter ablation as a safe alternative.

Conclusions:

• The 2019 ESC guidelines prioritize catheter ablation for SVT management, reflecting its established efficacy and safety.
• Antiarrhythmic drug use for SVT is refined, with caution advised due to proarrhythmic risks.
• Specific recommendations provide safer SVT treatment options for pregnant women, including radiation-free ablation techniques.